Claims

1. Use of a storage stable composition in the manufacture of a medicament for stimulating bone growth in a subject with a bone fracture, said storage-stable composition comprising:

   a) a PTHrP analogue whose sequence is [Glu ^{22,25}, Leu^{23,28,31}, Aib^{29},Lys^{26,30}]hPTHrP(1-34)NH_2 (SEQ ID NO.2); and

   b) an effective amount of a pH buffer to maintain the pH in a range of ~~about~~ 4.5 to ~~about~~ 5.6.

2. The use according to claim 1 wherein said subject is administered the medicament by single daily subcutaneous injection of an amount of said composition containing from ~~about~~ 75 to ~~about~~ 80 μg of [Glu ^{22,25}, Leu^{23,28,31}, Aib^{29},Lys^{26,30}]hPTHrP(1-34)NH_2 (SEQ ID NO.2).

3. The use according to claim 2 wherein said storage-stable composition further comprises phenol in a concentration from ~~about~~ 0.25 to ~~about~~ 5 mg/mL.

4. The use according to any one of claims 1 to 3 wherein said pH buffer is an acetate buffer.

5. The use according to claim 1 wherein said subject is administered the medicament by single daily subcutaneous injection of an amount of said composition containing from ~~about~~ 40 to ~~about~~ 45 μg of [Glu ^{22,25}, Leu^{23,28,31}, Aib^{29},Lys^{26,30}]hPTHrP(1-34)NH_2 (SEQ ID NO.2).

6. The use according to claim 5 wherein said storage-stable composition further comprises phenol in a concentration from ~~about~~ 0.25 to ~~about~~ 5 mg/mL.

7. The use according to any one of claims 5 to 6 wherein said pH buffer is an acetate buffer.

8. Use of a storage stable composition according to claim 1, wherein said pH is ~~about~~ 5.1.

9. A storage stable composition for use as a medicament for stimulating bone growth in a subject with a bone fracture, said storage-stable composition comprising:

a) a PTHrP analogue whose sequence is [Glu ^{22,25}, Leu^{23,28,31}, Aib^{29},Lys^{26,30}]hPTHrP(1-34)NH_2 (SEQ ID NO.2); and
b) an effective amount of a pH buffer to maintain the pH in a range of ~~about~~ 4.5 to ~~about~~ 5.6.

10. Use of a storage stable composition according to claim 9 wherein said subject is administered the medicament by single daily subcutaneous injection of an amount of said composition containing from ~~about~~ 75 to ~~about~~ 80 μG of [Glu ^{22,25}, Leu^{23,28,31}, Aib^{29},Lys^{26,30}]hPTHrP(1-34)NH_2 (SEQ ID NO.2).

11. Use of a storage stable composition according to claim 10 wherein said storage-stable composition further comprises phenol in a concentration from ~~about~~ 0.25 to ~~about~~ 5 mg/mL.

12. Use of a storage stable composition according to any one of claims 9 to 11 wherein said pH buffer is an acetate buffer.

13. Use of a storage stable composition according to claim 9 wherein said subject is administered the medicament by single daily subcutaneous injection of an amount of said composition containing from ~~about~~ 40 to ~~about~~ 45 μG of [Glu ^{22,25}, Leu^{23,28,31}, Aib^{29},Lys^{26,30}]hPTHrP(1-34)NH_2 (SEQ ID NO.2).

14. Use of a storage stable composition according to claim 13 wherein said storage-stable composition further comprises phenol in a concentration from ~~about~~ 0.25 to ~~about~~ 5 mg/mL.

15. Use of a storage stable composition according to any one of claims 13 to 14 wherein said pH buffer is an acetate buffer.

16. Use of a storage stable composition according to claim 9, wherein said pH is ~~about~~ 5.1.